AlphAIAlphAI — Financial news for AI agents
investing.comOCT 292 min read$BSX

Truist reiterates Buy on Boston Scientific stock amid 2027 outlook

Truist reiterated a Buy rating and $51 target on Boston Scientific (BSX) despite 2027 growth challenges from a cyberattack. The firm expects negative growth in 2027 but sees a recovery in 2028. BSX's Q3 2026 results missed EPS estimates but beat revenue forecasts. Multiple analysts adjusted price targets and ratings due to the outlook.

Original reporting
investing.com
Published Oct 29, 2026, 5:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 5:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$BSX
Bearish
high confidence
Mentioned
$BSX
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$BSXBearishMed
01

Why it matters

Analyst consensus now reflects weaker growth outlook, with price targets ranging from $48 to $52 and a shift to Perform from Outperform.

02

Market read

Analyst rating and target revisions provide fresh guidance that could move BSX lower in the short term.

03

What to watch

Potential upside from delayed product launches in 2028 and a 5% portfolio growth projection.

Relevance 7/10Novelty 6/10Timing: today

Background

Boston Scientific reported mixed Q3 2026 results, missing EPS expectations and attributing the shortfall to a cyber‑attack that disrupted manufacturing and shipping.

Company-level read

Ticker impact

$BSXBearishHigh confidence
Context

Truist reiterated a Buy rating with a $51 price target and highlighted a cyber‑attack‑driven negative outlook for 2027, while multiple analysts cut price targets and downgraded the stock.

Expected impact

likely pressure as the market prices in weaker 2027 guidance and lower targets

Evidence & confidence

Multiple sell‑side firms (Oppenheimer, RBC, Mizuho, Canaccord) reduced targets and ratings, indicating consensus on reduced growth expectations.

Market effects

Sector

Medical device sector may face broader scrutiny on cyber‑risk and growth forecasts.

Regional

U.S. healthcare stocks could see modest pullback amid heightened risk perception.

Global

Limited; impact confined to Boston Scientific and peers.

Counterpoint

What could challenge this read

If the cyber‑attack impact is overstated, the stock could rebound on its strong cash flow and pipeline.

Key entities

  • analyst
    Truist Securities

    Reiterated Buy rating and $51 price target.

  • analyst
    Oppenheimer

    Downgraded to Perform.

  • analyst
    RBC Capital

    Reduced target to $52.

  • analyst
    Mizuho

    Cut target to $50.

  • analyst
    Canaccord

    Reduced target to $48.

Read at source← All news

StoryBoston Scientific reports Q3 2026 results and cuts FY2026 outlook after cyberattack

Also covered by

5 outlets

Related articles

OCT 29
$BSXHighAI 8/10

What Is Behind The Move In Boston Scientific Stock?

Boston Scientific (BSX) stock fell 5.8% after Q3 2026 results and lowered outlook due to a cyberattack. The attack reduced sales by $150M. Revenue was $5.14B, beating estimates, but growth slowed. Full-year revenue growth forecast cut to 4%. Peers mostly rose. BSX stock down 58.6% over a year.

finance.yahoo.com2 min
OCT 29
$BSXMedAI 8/10

Boston Scientific Corp (BSX) (Q3 2026) Earnings Call Highlights: Cyber Incident Slashes

Boston Scientific (BSX) reported Q3 2026 earnings below expectations due to a cyber incident, with organic sales growth of 1.5% and adjusted EPS of $0.73. The company expects continued pressure in 2027 but anticipates growth from new product launches and market expansions. BSX plans $500M in savings from restructuring and expects to close the Penumbra acquisition in early 2027.

finance.yahoo.com7 min
OCT 29
$BSXMedAI 8/10

Boston Scientific Corporation net sales up 1.5 % to USD 5.138B in Q3 2026

Boston Scientific (BSX) reported Q3 2026 net sales of $5.138B, up 1.5%. GAAP EPS was $0.40, down from $0.51 a year ago, while adjusted EPS was $0.73, slightly lower than the previous year. The company faced challenges, including a cybersecurity incident, but remains confident in its long-term strategy. Full-year net sales growth is now expected to be around 4.25% on a reported basis and 3.75% organically, with adjusted EPS projected between $3.16 and $3.18.

medicalbuyer.co.in5 min
OCT 29
$BSXMed

Oppenheimer downgrades Boston Scientific stock rating on growth concerns

Oppenheimer downgraded Boston Scientific (BSX) to Perform from Outperform due to growth concerns, citing weak Q3 results and a lack of expected growth in 2027. The stock is down 55.5% YTD to $42.43. BSX reported Q3 revenue of $5.14B, meeting expectations but missing EPS forecasts. Analysts lowered price targets and earnings estimates, citing a cyberattack's impact and declining product franchises. BSX's organic growth was 1.5% YOY, below guidance.

investing.com2 min
OCT 29
$MUMed

Wall Street ends higher as Fed holds key rate steady

U.S. stock indexes rose after the Fed kept rates unchanged, upgrading its economic outlook but noting elevated inflation. Investors expect a December rate hike. Micron and SK Hynix shares surged on strong earnings. Microsoft gained, while Alphabet dropped in extended trading. The Dow, S&P 500, and Nasdaq all closed higher.

newstribune.com7 min